trending Market Intelligence /marketintelligence/en/news-insights/trending/1hiLcpS0mQVD4os0HMJ2Ag2 content
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

In This List

DelMar Pharmaceuticals prices $6.8M common stock, warrants offering

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry


IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

The Market Intelligence Platform

DelMar Pharmaceuticals prices $6.8M common stock, warrants offering

DelMar Pharmaceuticals Inc. priced an offering of securities to raise about $6.8 million in gross proceeds.

The company will issue 6,750,000 common shares and an equal number of warrants, for a combined price of $1 each. The five-year warrants are immediately exercisable at $1 per common share.

Some investors will receive a pre-funded warrant instead of a common share.

Maxim Group LLC is acting as the book-running manager and Dawson James Securities Inc. is acting as a co-manager.

The Vancouver, Canada-based biopharmaceutical company also granted underwriters a 45-day option to buy up to an additional 1,012,500 common shares and warrants to buy up to 1,012,500 common shares at the same price.

The offering is expected to close on or about Aug. 16.

DelMar Pharmaceuticals develops anti-cancer therapies to treat cancer patients who have failed to respond to modern therapy.